Sexually Transmitted Diseases Treatment Market Five Years Forecast Skeleton With Key Companies Merck, Pfizer, GlaxoSmithKline, Vertex Pharmaceuticals, Roche, Gilead Sciences, AbbVie

Increasing sexually transmitted disease burden is fueling growth of the STDs treatment market. Among 20 STDs, the most common are Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus (HIV). For instance, according to Centers for Disease Control and Prevention (CDC), in year 2016, 1,598,354 cases of Chlamydia trachomatis infection were reported in the U.S., corresponding to 497.3 cases per 100,000 in 2015. Furthermore, 468,514 gonorrhea cases were reported for a rate of 145.8 cases per 100,000 population, an increase of 18.5% from 2015. This increasing incidence of STDs is also due to the unprotected sexual practice, which in turn fueling demand for STDs treatment. For instance, according to World Health Organization (WHO), unsafe sex is second most common risk factor for increasing disease burden.

The number of products in pipeline for HIV treatment are high, which is expected to propel growth of the sexually transmitted disease treatment market. For instance, in 2017, GSK and ViiV Healthcare applied in European Medicines Agency (EMA) and US Food and Drug Administration (FDA), for regulatory affiliation for a single-tablet, two-drug regimen of dolutegravir (by ViiV Healthcare) and rilpivirine (by Janssen) used for treatment of HIV-1 infection. Moreover, other drug candidates in pipeline includes – PrEP, PRO140 with ibalizumab, BMS- 955176, which are expected to be launched in the forecast period. Moreover, governments are focusing on funding research and development programs, which is expected to aid in growth of the market. For instance, British Columbia Center for Disease Control sponsored doxycycline (drug) studies for indication of syphilis and other sexually transmitted infection, which is in early phase I clinical trial as of 2016.

Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/2005

Moreover, increasing governmental initiatives to spread awareness through organization of campaigns and free diagnostic camps is also expected to augment growth of the STDs treatment market. For instance, Centers for Disease Control and Prevention (CDC) launched Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies, or STD-AAPPS, in 2014. Moreover, in 2018, Thunder Bay Group—HIV / AIDS / hepatitis C education and support services provider— expanded the access of hepatitis C medicine for individuals with level 2 hepatitis C, after negotiating with the provinces and drug manufacturers.

However, growth of the sexually transmitted disease treatment market is expected to be restrained by low rate of screening for diseases and late diagnosis of the disease such as HIV.

Sexually Transmitted Diseases Treatment market - Regional Analysis

Geographically, the sexually transmitted diseases treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant market, owing to rising government initiative for disease awareness and implementation of prenatal screening programs. However, Asia Pacific is expected to be fastest growing market for sexually transmitted diseases treatment, due to high incidence of sexually transmitted infections, owing to unprotected sexual practices in the region. For instance, according to Joint United Nations Programme on HIV and AIDS (UNAIDS), Asia Pacific had the second-highest number of people living with HIV in the world i.e. 5.1 million as of 2016, Moreover, China, India, and Indonesia accounts for three quarters of the total people living with HIV in Asia Pacific.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2005

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.